March 28, 2024 S&P 500 Soars 10% in Q1, Outstrips Bullish Forecasts
March 20, 2024 Fed Grapples With Rate Decision Amid Inflation Concerns
March 19, 2024 Bank of Japan Ends Era of Negative Rates
Apple: AI Strategy To Help Fight DOJ, Kickstart Growth
Nvidia Stock Priced As If It Will Deliver Us The Moon
Amazon: Still Cheap Even After Robust Rally
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
March 6, 2024 Navigating GBP Forecast: Mistakes To Avoid In Forex Trading
February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice
February 15, 2024 Vanskelig å Få Refinansiering: Why Was Your Refinancing Loan Denied?
Clarus Therapeutics Holdings (CRXT) stock forecast for 2025
Updated: March 25, 2024 (06:53)
Sector: HealthcareThe share price of Clarus Therapeutics Holdings, Inc. (CRXT) now
50/200 Day Moving Average: $ / $
This figure corresponds to the Average Price over the previous 50/200 days. For Clarus Therapeutics Holdings stocks, the 50-day moving average is the support level today.
For Clarus Therapeutics Holdings stocks, the 200-day moving average is the support level today.
Are you interested in Clarus Therapeutics Holdings, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Clarus Therapeutics Holdings stock price in 2025. How much will one Clarus Therapeutics Holdings share be worth in 2025? Is it worth taking profit / loss on CRXT stock now or waiting? What are analysts' forecasts for Clarus Therapeutics Holdings stock?
We forecast Clarus Therapeutics Holdings stock performance using neural networks based on historical data on CRXT stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Clarus Therapeutics Holdings, Inc. stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Clarus Therapeutics Holdings analysts is $. Today 200 Day Moving Average is the support level ( $). 50 Day Moving Average is the support level ( $).
Historical and forecast chart of Clarus Therapeutics Holdings, Inc. stock
The chart below shows the historical price of Clarus Therapeutics Holdings stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the CRXT stock price can be found in the table below.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. the company’s first commercial product is JATENZO. It is headquartered in Northbrook, IL.
Clarus Therapeutics Holdings (CRXT) Forecast for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 0.00 | 0.00 | 0.00 | 32.26 % |
Feb | 0.00 | 0.00 | 0.00 | 26.35 % |
Mar | 0.00 | 0.00 | 0.00 | 29.51 % |
Apr | 0.00 | 0.00 | 0.00 | 22.45 % |
May | 0.00 | 0.00 | 0.00 | 26.22 % |
Jun | 0.00 | 0.00 | 0.00 | 23.16 % |
Jul | 0.00 | 0.00 | 0.00 | 25.75 % |
Aug | 0.00 | 0.00 | 0.00 | 35.28 % |
Sep | 0.00 | 0.00 | 0.00 | 20.94 % |
Oct | 0.00 | 0.00 | 0.00 | 20.79 % |
Nov | 0.00 | 0.00 | 0.00 | 23.08 % |
Dec | 0.00 | 0.00 | 0.00 | 27.43 % |
Clarus Therapeutics Holdings information and performance
N/A
Market capitalization of the Clarus Therapeutics Holdings, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of CRXT shares in the company outstanding by the market price of one share.
EBITDA of Clarus Therapeutics Holdings is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Clarus Therapeutics Holdings price target for 2025 by month
Target values for the price of one Clarus Therapeutics Holdings share for Jan 2025.
In Jan, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 32.255% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Feb 2025.
In Feb, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 26.348% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Mar 2025.
In Mar, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 29.508% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Apr 2025.
In Apr, the Positive dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 22.451% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for May 2025.
In May, the Positive dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 26.216% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Jun 2025.
In Jun, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 23.163% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Jul 2025.
In Jul, the Positive dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 25.751% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Aug 2025.
In Aug, the Positive dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 35.279% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Sep 2025.
In Sep, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 20.936% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Oct 2025.
In Oct, the Positive dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 20.792% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Nov 2025.
In Nov, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 23.077% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Target values for the price of one Clarus Therapeutics Holdings share for Dec 2025.
In Dec, the Negative dynamics for Clarus Therapeutics Holdings, Inc. shares will prevail with possible monthly volatility of 27.433% volatility is expected.
Pessimistic target level: 0.00
Optimistic target level: 0.00
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.